There have been a number of advancements in the treatment of follicular lymphoma in 2024. Additionally, Monjuvi (tafasitamab) has been shown to have positive results regarding disease progression for ...
In this video, Leo I. Gordon, MD, FACP, discusses the growing view that follicular lymphoma could be viewed as “curable.” ...
A dog provided crucial companionship during the author's cancer treatment and pandemic isolation, highlighting the emotional support pets can offer. Post-treatment, the author embraced life by ...
Media ReleaseCOPENHAGEN, Denmark; November 3, 2025 More than 20 abstracts, including seven oral presentations, highlight advancements from the epcoritamab development program supporting the expanded ...
Learn about follicular lymphoma, its symptoms, causes, and treatment options. Understand this slow-growing cancer for early ...
Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end. Now, a ...
Fixed-Duration Subcutaneous Mosunetuzumab Shows Durable Responses, Safety in R/R Follicular Lymphoma
A phase 1/2 study showed durable remission, manageable safety in pts with R/R follicular lymphoma who received fixed-duration mosunetuzumab.in.
(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback